Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Total Current Liabilities

All obligations due within one year.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total current liabilities of $12.62M in Q2 FY2026

Q2 FY2026 total current liabilities was $12.62M.

Context

  • Total current liabilities amounted to 9.8% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.62M+28.7% QoQ
Last fiscal yearDec 2025
$11.01M+42.5% YoY
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+42.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
11.01M USD
Year-over-year change
+42.5%
1-year CAGR
+42.5%

Total Current Liabilities vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
  • Total current liabilities amounts to 9.8% of total assets for ATTO, versus a peer median of 12.1%.
ATTO Competitors
Total Current Liabilities for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALMSAlumis Inc. Common StockJun 2026$76.23M USD-10.9%+76.4%13.6%
MLTXMoonLake ImmunotherapeuticsMar 2026$46.11M USD+92.3%+81.0%11.5%
ANABAnaptysBio, Inc.Mar 2026$41.7M USD-5.3%+14.0%12.6%
ORKAOruka Therapeutics, Inc.Sep 2026$31.78M USD+51.6%+138.6%2.6%
ACRSAclaris Therapeutics, Inc.Mar 2026$27.37M USD+27.2%+9.3%13.8%
CNTBConnect Biopharma Holdings LimitedDec 2025$13.61M USD+60.9%-4.5%24.3%
ATTOAttovia Therapeutics, Inc.Jun 2026$12.62M USD——9.8%
ZURAZura Bio LimitedMar 2026$11.75M USD-44.3%-5.7%5.1%
QTTBQ32 Bio Inc.Mar 2026$10.67M USD-26.8%-41.9%16.8%
EVMNEvommune, Inc.Mar 2026$10.6M USD-51.9%—3.3%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€9.51M EUR——5.7%
Peer median (excluding ATTO) —-5.3%+11.7%12.1%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.